Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;24(3):258-264.
doi: 10.1111/1744-9987.13435. Epub 2019 Oct 25.

Iron Infusion and Induced Hypophosphatemia: The Role of Fibroblast Growth Factor-23

Giuseppe Coppolino  1 , Ramona Nicotera  1 , Valeria Cernaro  2 , Sebastiano Calimeri  2 , Giuseppe Leonardi  1 , Sonia Cosentino  1 , Alessandro Comi  1 , Cinzia Donato  3 , Citraro Maria Lucia  1 , Michele Provenzano  1 , Ashour Michael  1 , Michele Andreucci  1
Affiliations
Review

Iron Infusion and Induced Hypophosphatemia: The Role of Fibroblast Growth Factor-23

Giuseppe Coppolino et al. Ther Apher Dial. 2020 Jun.

Abstract

The mechanism of action of fibroblast growth factor-23 (FGF23) is becoming increasingly clearer as a result of studies that have defined its structure and pleiotropic effects. Furthermore, data are emerging on the effects exerted on this hormone by iron administration. Ten main iron formulations are recognized (with clear differences in composition and possible reactions of intolerance and anaphylaxis), which are indicated for iron deficiency anemia, including nephropathic subjects, as suggested by medical guidelines. With some types of iron formulation (especially iron carboxymaltose) a particular side effect has been observed: hypophosphatemia, mediated by FGF23. This review aims to draw attention to this correlation and the contradiction represented by the presence of both positive and negative modulation by FGF23, with the effects induced by its increase even after long-term treatment with iron formulation. However, more evidence is needed to understand the reasons for this differential stimulation.

Keywords: Fibroblast growth factor-23; Hypophosphatemia; Iron infusion.

PubMed Disclaimer

References

REFERENCES

    1. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35.
    1. Martin A, David V, Quarles LD. Regulation and function of the FGF23/Klotho endocrine pathways. Physiol Rev 2012;92:131-55.
    1. Cernaro V, Santoro D, Lacquaniti A et al. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. Int J Nephrol Renovasc Dis 2016;9:11-9.
    1. Bhattacharyya N, Chong WH, Gafni RI, Collins MT. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab 2012;23:610-8.
    1. Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 2012;8:276-86.

MeSH terms

LinkOut - more resources